The drugmaker told investors that the actual-use trial failed to meet the primary objectives.
View on a quarter-by-quarter basis the competitive market for four new hepatitis-C treatments and track how Gilead Sciences' Harvoni became the market leader within months of receiving approval from the FDA.
The agency approved Sanofi's and Regeneron's Praluent, one of the most hyped new drugs of 2015.
Taking a look back at what's happened—and what hasn't happened—on the healthcare communications policy front so far this summer
The focus on boosting physician referrals might appear contrary to the current obsession with patient-centric marketing.
The modern healthcare landscape is complicated, and the terrain is even more gnarled for life sciences companies trying to bring new products to market.